Evidence map›Paper›PMID 41919393›Full record

Trial reportCirculation. Arrhythmia and electrophysiology2026

Lesion Durability of the Second Generation Pentaspline Pulsed Field Ablation Catheter

Vivek Y Reddy, Jan Petru, Moritoshi Funasako, Silvia Canepa, Camille Metzdorff, Brynn Okeson, Evripidis Mikos, Tobias Oesterlein, Sarah R Gutbrod, Brendan E Koop and 1 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Arrhythmia and electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06175234 (A Study Evaluating the User Experience With the FARAVIEW™ Technology of the RHYTHMIA HDx™ Mapping System When Used With the FARAWAVE NAV™ Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06175234 nacompletednot on this map

A Study Evaluating the User Experience With the FARAVIEW™ Technology of the RHYTHMIA HDx™ Mapping System When Used With the FARAWAVE NAV™ Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation

TypeinterventionalSponsorBoston Scientific CorporationRan2024 to 2025Enrolled50ConditionsAtrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial FibrillationArmsAblation Treatment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Incremental value of electroanatomical mapping during pentaspline pulsed field pulmonary vein isolation: the MAP-PFA pilot randomized trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vivek Y ReddyHomolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., P.N.).ORCID 0000-0002-5638-4993
Jan PetruHomolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., P.N.).
Moritoshi FunasakoHomolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., P.N.).ORCID 0000-0002-1620-3924
Silvia CanepaBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).
Camille MetzdorffBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).
Brynn OkesonBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).ORCID 0000-0002-6912-7259
Evripidis MikosBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).ORCID 0009-0003-9572-8618
Tobias OesterleinBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).
Sarah R GutbrodBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).
Brendan E KoopBoston Scientific Corporation, St. Paul, MN (S.C., C.M., B.O., E.M., T.O., S.R.G., B.E.K.).ORCID 0009-0006-5786-627X
Petr NeuzilHomolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., P.N.).ORCID 0000-0003-4334-8165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRemapping studies have evaluated chronic lesion durability of the first-generation pentaspline pulsed field ablation (PFA) catheter that did not have integrated electroanatomical mapping. By invasive remapping, this first-in-human study evaluated the durability of lesions facilitated by the integration of the navigation-enabled pentaspline PFA catheter and mapping system in patients with atrial fibrillation.

methodsThe

resultsAfter index ablation in 20 patients with the pentaspline PFA catheter, remaps were performed 60 days later in 17 patients, demonstrating a high rate of lesion durability in the pulmonary veins (95%) and posterior wall (86%).

conclusionsBy facilitating real-time visualization of catheter positioning and acute lesion estimation through tags, the second-generation map-and-ablate pentaspline PFA catheter and integrated mapping system may enhance procedural success. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06175234.

Indexed as

Atrial FibrillationCardiac CathetersCatheter AblationPulmonary VeinsAction PotentialsAgedElectrophysiologic Techniques, CardiacEquipment DesignFemaleHeart RateHumansIrreversible Electroporation TherapyMaleMiddle AgedTime FactorsTreatment Outcomeatrial fibrillationcatheter ablationpulsed field ablation

Identifiers

PMID41919393
PMCPMC13098650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.